Inmed to participate in fierce biotech webinar on neuroinflammation in alzheimer's disease

Vancouver, british columbia--(newsfile corp. - october 24, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming fierce biotech webinar "alzheimer's outlook - neuroinflammation, the next step," on november 12th, 2024. inmed's senior vice president of preclinical research and development, dr. eric hsu, will join a panel of experts to speak about recent trends in alzheimer's disease research and the targeting of neuroinflammation to restrict disease progression.
INM Ratings Summary
INM Quant Ranking